{"nctId":"NCT01757184","briefTitle":"Acid Lipase Replacement Investigating Safety and Efficacy (ARISE) in Participants With Lysosomal Acid Lipase Deficiency","startDateStruct":{"date":"2013-01-22","type":"ACTUAL"},"conditions":["Lysosomal Acid Lipase Deficiency"],"count":66,"armGroups":[{"label":"Double-blind Sebelipase Alfa","type":"EXPERIMENTAL","interventionNames":["Drug: Sebelipase Alfa"]},{"label":"Double-blind Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Open-label Sebelipase Alfa/Sebelipase Alfa","type":"EXPERIMENTAL","interventionNames":["Drug: Sebelipase Alfa"]},{"label":"Open-label Placebo/Sebelipase Alfa","type":"EXPERIMENTAL","interventionNames":["Drug: Sebelipase Alfa"]}],"interventions":[{"name":"Sebelipase Alfa","otherNames":["SBC-102"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participant and/or participant's parent or legal guardian provided informed consent.\n* Participant was ≥ 4 years of age on the date of informed consent.\n* Deficiency of LAL enzyme activity confirmed by dried blood spot testing at screening.\n* Alanine aminotransferase ≥ 1.5x upper limit of normal on 2 consecutive screening measurements obtained at least 1 week apart.\n* Female participants of childbearing potential must not have been pregnant or breastfeeding and must have agreed to use a medically acceptable method of preventing contraception from screening until 4 weeks after the last dose of study drug.\n* Participant receiving lipid-lowering therapies must have been on a stable dose of the medication for at least 6 weeks prior to randomization and was willing to remain on a stable dose for at least the first 32 weeks of treatment in the study.\n* Participant receiving medications for the treatment of nonalcoholic fatty liver disease must have been on a stable dose for at least 16 weeks prior to randomization and was willing to remain on a stable dose for at least the first 32 weeks of treatment in the study.\n\nExclusion Criteria:\n\n* Severe hepatic dysfunction (Child-Pugh Class C).\n* Other medical conditions or comorbidities, which, in the opinion of the Investigator, would have interfered with study compliance or data interpretation.\n* Previous hematopoietic or liver transplant procedure.\n* Received treatment with high-dose corticosteroids (acute or chronic) within 26 weeks. (Note: Participants receiving maintenance therapy with low-dose oral, intranasal, topical, or inhaled corticosteroids were considered eligible for the study).\n* Known hypersensitivity to eggs.\n* Participated in a study employing an investigational medicinal product within 4 weeks prior to randomization.","healthyVolunteers":false,"sex":"ALL","minimumAge":"4 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage Of Participants Achieving Alanine Aminotransferase Normalization","description":"Alanine aminotransferase (ALT) normalization was defined as an abnormal baseline value (ALT \\> the age- and gender-specific upper limit of normal \\[ULN\\] provided by the central laboratory performing the assay) that becomes normal (\\< ULN). Alanine aminotransferase normalization was evaluated at the end of the Double-blind Period (the last double-blind assessment) and at the end of the Open-label Period (last open-label assessment). Baseline for the Open-label Period was defined relative to the first infusion of sebelipase alfa, which occurred at Week 0 for participants in the sebelipase alfa/sebelipase alfa group and Week 22 for participants in the placebo/sebelipase alfa group. The last open-label assessment varied by participant, depending on whether a participant completed treatment through Week 256 or discontinued prior to this timepoint to transition out of clinical study settings.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"56","spread":null},{"groupId":"OG003","value":"37","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline In Low-density Lipoprotein Cholesterol (LDL-C)","description":"Relative reduction (percentage change from baseline) in LDL-C, as assessed by laboratory measurements was evaluated at the end of the Double-blind Period and at the end of the Open-label Period. Baseline for the Open-label Period was defined relative to the first infusion of sebelipase alfa, which occurred at Week 0 for participants in the sebelipase alfa/sebelipase alfa group and Week 22 for participants in the placebo/sebelipase alfa group. The last open-label assessment varied by participant, depending on whether a participant completed treatment through Week 256 or discontinued prior to this timepoint to transition out of clinical study settings.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-28.42","spread":"22.304"},{"groupId":"OG001","value":"-6.25","spread":"13.015"},{"groupId":"OG002","value":"-19.74","spread":"33.262"},{"groupId":"OG003","value":"-18.09","spread":"33.685"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline In Non-high Density Lipoprotein Cholesterol (Non-HDL-C)","description":"Relative reduction (percent change from baseline) in non-HDL-C, as assessed by laboratory measurements, was evaluated at the end of the Double-blind Period and the Open-label Period. Baseline for the Open-label Period was defined relative to the first infusion of sebelipase alfa, which occurred at Week 0 for participants in the sebelipase alfa/sebelipase alfa group and Week 22 for participants in the placebo/sebelipase alfa group. The last open-label assessment varied by participant, depending on whether a participant completed treatment through Week 256 or discontinued prior to this timepoint to transition out of clinical study settings.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.97","spread":"18.612"},{"groupId":"OG001","value":"-6.94","spread":"10.922"},{"groupId":"OG002","value":"-19.75","spread":"26.875"},{"groupId":"OG003","value":"-18.34","spread":"29.177"}]}]}]},{"type":"SECONDARY","title":"Percentage Of Participants Achieving Aspartate Aminotransferase Normalization","description":"Aspartate aminotransferase (AST) normalization was defined as an abnormal baseline value (AST \\> the age- and gender-specific ULN provided by the central laboratory performing the assay) that becomes normal (\\< ULN). AST normalization was evaluated at the end of the Double-blind Period (the last Double-blind assessment) and at the end of the Open-label Period (last open-label assessment).\n\nBaseline for the Open-label Period was defined relative to the first infusion of sebelipase alfa, which occurred at Week 0 for participants in the sebelipase alfa/sebelipase alfa group and Week 22 for participants in the placebo/sebelipase alfa group. The last open-label assessment varied by participant, depending on whether a participant completed treatment through Week 256 or discontinued prior to this timepoint to transition out of clinical study settings.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"69","spread":null},{"groupId":"OG003","value":"62","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline In Triglycerides","description":"Relative reduction (percent change from baseline) in triglycerides, as assessed by laboratory measurements, was evaluated at the end of the Double-blind Period and the Open-label Period. Baseline for the Open-label Period was defined relative to the first infusion of sebelipase alfa, which occurred at Week 0 for participants in the sebelipase alfa/sebelipase alfa group and Week 22 for participants in the placebo/sebelipase alfa group. The last open-label assessment varied by participant, depending on whether a participant completed treatment through Week 256 or discontinued prior to this timepoint to transition out of clinical study settings.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-25.45","spread":"29.411"},{"groupId":"OG001","value":"-11.14","spread":"28.827"},{"groupId":"OG002","value":"-11.87","spread":"34.580"},{"groupId":"OG003","value":"-19.63","spread":"27.066"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline In High-density Lipoprotein Cholesterol (HDL-C)","description":"Relative increase (percent change from baseline) in HDL-C, assessed by laboratory measurements, was evaluated at the end of the Double-blind Period and the Open-label Period. Baseline for the Open-label Period was defined relative to the first infusion of sebelipase alfa, which occurred at Week 0 for participants in the sebelipase alfa/sebelipase alfa group and Week 22 for participants in the placebo/sebelipase alfa group. The last open-label assessment varied by participant, depending on whether a participant completed treatment through Week 256 or discontinued prior to this timepoint to transition out of clinical study settings.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.57","spread":"16.833"},{"groupId":"OG001","value":"-0.29","spread":"12.360"},{"groupId":"OG002","value":"31.65","spread":"28.971"},{"groupId":"OG003","value":"34.78","spread":"29.927"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline In Liver Fat Content","description":"Decrease in liver fat content, as assessed by magnetic resonance imaging (MRI), was evaluated in participants for whom imaging was performed. Baseline for the Open-label Period was defined relative to the first infusion of sebelipase alfa, which occurred at Week 0 for participants in the sebelipase alfa/sebelipase alfa group and Week 22 for participants in the placebo/sebelipase alfa group. The last open-label assessment varied by participant, depending on whether a participant completed treatment through Week 256 or discontinued prior to this timepoint to transition out of clinical study settings.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-31.98","spread":"26.763"},{"groupId":"OG001","value":"-4.21","spread":"15.559"},{"groupId":"OG002","value":"-9.89","spread":"32.892"},{"groupId":"OG003","value":"-0.93","spread":"37.233"}]}]}]},{"type":"SECONDARY","title":"Participants With Improvement In Liver Histopathology (Decrease Of > 5% In Hepatic Steatosis Score)","description":"The number of participants who had an improvement in hepatic histopathology (defined as a decrease of \\> 5% in hepatic steatosis score, assessed by morphometry), as determined by blinded central pathologist review, in the participants for whom liver biopsy was performed. Baseline for the Open-label Period was defined relative to the first infusion of sebelipase alfa, which occurred at Week 0 for participants in the sebelipase alfa/sebelipase alfa group and Week 22 for participants in the placebo/sebelipase alfa group.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"7","spread":null},{"groupId":"OG003","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline In Liver Volume","description":"Relative reduction (percent change from baseline) in liver volume, as assessed by MRI, was evaluated in participants for whom imaging was performed. Baseline for the Open-label Period was defined relative to the first infusion of sebelipase alfa, which occurred at Week 0 for participants in the sebelipase alfa/sebelipase alfa group and Week 22 for participants in the placebo/sebelipase alfa group. The last open-label assessment varied by participant, depending on whether a participant completed treatment through Week 256 or discontinued prior to this timepoint to transition out of clinical study settings.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.28","spread":"10.510"},{"groupId":"OG001","value":"-2.66","spread":"10.107"},{"groupId":"OG002","value":"-24.04","spread":"15.792"},{"groupId":"OG003","value":"-21.55","spread":"11.727"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":36},"commonTop":["Headache","Nasopharyngitis","Pyrexia","Diarrhoea","Upper respiratory tract infection"]}}}